BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Boston Biomedical Research Institute Scientists Contribute to the Development of Potential Therapeutics for Toxic Shock Syndrome


6/29/2007 12:06:17 PM

WATERTOWN, Mass., June 28 /PRNewswire-USNewswire/ -- Published in this month's issue of the journal Nature Medicine, a collaborative team of scientists from the University of Illinois, the University of Minnesota Medical School and the Boston Biomedical Research Institute describe engineered proteins that completely neutralize the lethal activity of a bacterial superantigen in animal models. Their work holds great promise for the development of new therapeutics for toxic shock syndrome, a condition that is characterized by high fever and hypotension and can lead to multi-organ failure and death, and for which no treatment is currently available.

The research team, led by David M. Kranz from the University of Illinois and including members of the laboratories of Patrick M. Schlievert at the University of Minnesota Medical School and Eric J. Sundberg at the Boston Biomedical Research Institute, focuses on a class of toxins know as bacterial superantigens, which are secreted from many common bacteria, including Staphylococcus aureus and Streptococcus pyogenes, which cause toxic shock syndrome. These toxins have also been classified as biological weapons.

Superantigens function by interacting with receptor molecules on the surfaces of human immune system cells. These receptor molecules include the T cell receptor on T lymphocytes and major histocompatibility complex molecules on antigen presenting cells that normally carry out the presentation and recognition of antigens that initiate the tightly-controlled adaptive immune response required to clear the body of infection. Superantigen binding to these receptor molecules, however, results in the stimulation of an inordinate fraction of T lymphocytes and a massive release of the signaling molecules called cytokines that recruit other cells of the immune system, a cascade of biological signaling events that can ultimately lead to toxic shock syndrome.

The research team engineered a fragment of the T cell receptor that normally binds to a superantigen relatively weakly to associate with its superantigen target more than a million-fold tighter through a directed evolutionary process called yeast display. These engineered T cell receptor fragments were produced recombinantly in large quantities, shown to inhibit superantigen-mediated T cell activation in cell culture, and subsequently, used to effectively protect rabbits from lethal doses of superantigen.

Despite the intensive research efforts that have been directed at toxic shock syndrome and superantigens, therapeutics capable of neutralizing superantigen-mediated T cell activation in humans have to date been unavailable. The T cell receptor fragments described in this study represent an easily produced potential treatment for diseases mediated by bacterial superantigens.

About the Boston Biomedical Research Institute

Founded in 1968, Boston Biomedical Research Institute is a not-for-profit basic research institute dedicated to the understanding, treatment and prevention of a wide range of human diseases and conditions including cancer, cardiovascular diseases, neural and neuromuscular diseases, and degenerative diseases. For more information visit http://www.bbri.org.

Boston Biomedical Research Institute

CONTACT: Virginia S. Bowditch of the Boston Biomedical Research Institute,+1-617-658-7711, Sullivan@bbri.org



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES